Combining Experimental Compounds: Why Risk Cannot Be Assumed

Urgent first

If someone feels very unwell after injecting any product, or after combining products, get emergency care. In the US call 911; for suspected overdose or wrong amount, US Poison Help is 1-800-222-1222 (see Poison Help by Country). Tell responders everything that was taken. Do not stop or change prescribed medicines without asking the prescriber.

What "stack" means and what is claimed

"Stack" is a marketing and bodybuilding term for using several compounds together. It is not a medical or regulatory category, and a seller offering a "blend" is making a marketing claim. A 2026 narrative review describes online communities where self-injection, stacking and informal titration of weakly evidenced peptides are promoted, and where product-quality uncertainty and weak adverse-event reporting make harm hard to trace. [1] A narrative review is not a trial; it describes a pattern rather than measuring risk.

What is known about individual compounds

• BPC-157. A 2026 systematic review searched databases through 1 June 2026 and found only three human studies (30 participants in total): a retrospective knee-injection study (16), a retrospective bladder study (12) and an intravenous safety pilot (2). The review judged all three of poor quality and the certainty of evidence very low, and concluded BPC-157 should not be used clinically in humans outside regulated, high-quality trials. [2] None of these studies was a combination study.
• Other promoted peptides. FDA's list says, for example, that for MOTs-C it has not identified human exposure data, and that for several others it has no or limited safety information. [3] It notes serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction, and lists safety concerns for GHRP-6 such as a potential effect on cortisol and raised blood glucose. [3] (Some of these FDA entries are for nominations that were later withdrawn; the safety statements remain on the page.)

Safety is compound-specific. A problem described for one peptide does not transfer to another, and a lack of problems reported for one does not make a mixture safe.

Why mixtures add uncertainty

1. Each component has its own unknowns. FDA cites immunogenicity risk, aggregation and peptide-related impurities for many promoted peptides. [3]
2. Mixing adds quality questions. Identity, amount and sterility are already unverified for products sold outside regulated channels. [4][5]
3. Overlapping effects. For example, FDA's entry for GHRP-2 reports increased insulin requirement to maintain blood glucose in patients who received it. [3] Combining compounds that each affect glucose or hormones could compound those effects, but no study we read measured this.
4. Interactions with prescribed medicines. Even approved peptide medicines have labeled interactions. The Wegovy label says semaglutide lowers blood glucose and raises hypoglycemia risk with insulin or sulfonylureas, and that it delays gastric emptying, which may affect absorption of oral medicines. [6] Zepbound's label says the same about gastric emptying and advises switching to or adding non-oral contraception around starting and dose increases. [7]
5. Duplicating one drug class. Wegovy's label says use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended. [6]

Regulatory context

FDA has said that compounded drugs should only be used where a patient's medical needs cannot be met by an approved drug, and that compounded drugs are not reviewed for safety, effectiveness or quality. [8] FDA has also stated that retatrutide and cagrilintide cannot be used in compounding under federal law. [8]

Where to go next

See Peptide Safety: Adverse Events, Contamination and Injection Risks, Medication Interactions: Compound-Specific Examples and Claim Check: "Peptides Are Natural, So They Are Safe". This is not medical advice; talk with a licensed prescriber and pharmacist about every product you take.